Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Biocon Limited
BIOCONBiocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psoriasis molecules; and biosimilars products consisting of insulins, trastuzumab, pegfilgrastim, and bevacizumab. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer good, and agrochemical companies. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India. Address: 20th KM Hosur Road, Bengaluru, India, 560100
Analytics
Precio Objetivo de WallStreet
27 962.48 INRRelación P/E
26.7304Rentabilidad por dividendo
0.15 %Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave BIOCON
Análisis de dividendos BIOCON
Aumento del dividendo durante 5 años
200 %Crecimiento continuo
1 AñoRatio de pago medio en 5 años
18 %Tendencia del payout BIOCON
Valoración de la acción BIOCON
Finanzas BIOCON
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |